Mast Cell Clonal Disorders: Classification, Diagnosis and Management.

Autor: Onnes MC; Department of Allergology, University Medical Center Groningen, University of Groningen, and Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands., Tanno LK; Hospital Sírio Libanês, São Paulo, Brazil ; University Hospital of Montpellier, Montpellier, and Sorbonne Universités, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, 75013 Paris, France., Elberink JN; Department of Allergology, University Medical Center Groningen, University of Groningen, and Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands.
Jazyk: angličtina
Zdroj: Current treatment options in allergy [Curr Treat Options Allergy] 2016; Vol. 3 (4), pp. 453-464. Date of Electronic Publication: 2016 Nov 08.
DOI: 10.1007/s40521-016-0103-3
Abstrakt: Mast cell clonal disorders are characterized by the clonal proliferation of pathological mast cells as a result of somatic mutations in the KIT gene, most commonly the D816V mutation. Accumulation and degranulation of these cells causes a wide variety of symptoms. Mast cell clonal disorders can be divided into mastocytosis and monoclonal mast cell activation syndrome, depending of the level of clonality. The severity of mastocytosis varies from an indolent variant with a good prognosis, to an aggressive condition with short life expectancy. Diagnosis is based on demonstration of clonality and accumulation in the skin and in extracutaneous tissues. Treatment is highly individualized, and is based on the severity of the condition. Treatment of patients with indolent systemic mastocytosis is aimed at reducing symptoms, using histamine H1 and H2 receptor antagonists as a starting point. In addition, associated conditions such as osteoporosis must be treated. Treatment of advanced systemic mastocytosis is aimed at reducing mast cell load through cytoreductive therapy. The choice of such therapy depends on the KIT mutational status. Though currently there is no curative treatment available, promising new therapies such as midostaurin are emerging that have demonstrated success in reducing symptoms and improving quality of life.
Competing Interests: Merel C. Onnes and Dr. Luciana K. Tanno declare that they have no conflict of interest. Dr. Joanne N.G. Oude Elberink’s institute has received funds from Novartis for the phase II study of midostaurin in ISM. Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.
Databáze: MEDLINE
Externí odkaz: